Blockade of HERG channels by HIV protease inhibitors, The Lancet, vol.365, issue.9460, pp.682-688, 2005. ,
DOI : 10.1016/S0140-6736(05)70936-3
Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey, European Journal of Cardiovascular Prevention & Rehabilitation, vol.348, issue.Suppl. 1, pp.363-371, 2005. ,
DOI : 10.1097/01.hjr.0000173110.21851.a9
Drug-Induced QT Prolongation in Women During the Menstrual Cycle, JAMA, vol.285, issue.10, pp.1322-1328, 2001. ,
DOI : 10.1001/jama.285.10.1322
Electrocardiographic Findings in a Healthy Biracial Population, ARIC) Study Investigators, pp.453-462, 1998. ,
DOI : 10.1016/S0002-9149(97)00937-5
Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients, AIDS, vol.11, issue.6, pp.751-758, 1997. ,
DOI : 10.1097/00002030-199706000-00008
Heart rate variability in human immunodeficiency virus-positive individuals, International Journal of Cardiology, vol.94, issue.1, pp.1-6, 2004. ,
DOI : 10.1016/j.ijcard.2003.02.002
HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy, The Lancet, vol.362, issue.9397, pp.1758-60, 2003. ,
DOI : 10.1016/S0140-6736(03)14858-1
The association between the length of the QT interval and mortality in the cardiovascular health study, The American Journal of Medicine, vol.115, issue.9, pp.689-94, 2003. ,
DOI : 10.1016/j.amjmed.2003.07.014
Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham heart study experience), The American Journal of Cardiology, vol.67, issue.1, pp.55-63, 1991. ,
DOI : 10.1016/0002-9149(91)90099-7
QT interval as a cardiac risk factor in a middle aged population., Heart, vol.77, issue.6, pp.543-551, 1997. ,
DOI : 10.1136/hrt.77.6.543
Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.35, issue.4, pp.398-404, 2005. ,
DOI : 10.1016/j.clpt.2003.11.121
Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval, Therapeutic Drug Monitoring, vol.26, issue.1, pp.35-44, 2004. ,
DOI : 10.1097/00007691-200402000-00008
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data, Clinical Pharmacology & Therapeutics, vol.77, issue.6, pp.572-82, 2005. ,
DOI : 10.1016/j.clpt.2005.02.004